Hong Kong Consumer Services Stock News

SEHK:326
SEHK:326Entertainment

A Look At China Star Entertainment (SEHK:326) Valuation After Weak 2025 Results And Widening Losses

China Star Entertainment (SEHK:326) just released full year 2025 results showing revenue of HK$404.92 million and a net loss of HK$443.76 million, broadly in line with guidance for a sizeable annual loss. See our latest analysis for China Star Entertainment. The weak 2025 results come after a sharp re-rating in the market, with the share price at HK$6.70 and a 30 day share price return of 45.34%. This has fed into a very large 1 year total shareholder return, suggesting momentum has been...
SEHK:2096
SEHK:2096Pharmaceuticals

Assessing Simcere Pharmaceutical Group (SEHK:2096) Valuation After Strong 2025 Earnings Report

Simcere Pharmaceutical Group (SEHK:2096) has drawn fresh attention after reporting full year 2025 sales of CN¥7,731.41 million and net income of CN¥1,344.01 million, alongside a proposed final dividend of CN¥0.18 per share. See our latest analysis for Simcere Pharmaceutical Group. At a latest share price of HK$13.62, Simcere Pharmaceutical Group has seen a 16.91% 1 month share price return and an 80.98% 1 year total shareholder return. Recent earnings, dividend and leadership announcements...
SEHK:3808
SEHK:3808Machinery

A Look At Sinotruk (Hong Kong) (SEHK:3808) Valuation After Strong 2025 Results And Higher Final Dividend Proposal

Sinotruk (Hong Kong) (SEHK:3808) has drawn fresh attention after reporting full year 2025 results with higher sales and net income, along with a board proposal to lift the ordinary final dividend for shareholders. See our latest analysis for Sinotruk (Hong Kong). The share price has responded strongly, with a 30 day share price return of 14.48% and a 90 day gain of 51.71%. The 1 year total shareholder return of 137.59% points to building momentum around the healthier earnings and higher...
SEHK:9969
SEHK:9969Biotechs

Assessing InnoCare Pharma (SEHK:9969) Valuation After Its 2025 Profit Turnaround

Earnings shift draws fresh attention to InnoCare Pharma InnoCare Pharma (SEHK:9969) has drawn fresh attention after reporting full year 2025 sales of CN¥2,374.91 million and net income of CN¥642.47 million, compared with a net loss a year earlier. See our latest analysis for InnoCare Pharma. The earnings swing has coincided with strong price momentum, with a 31.19% 1 month share price return and a 24.16% year to date share price return at HK$15.52. The 1 year total shareholder return of...
SEHK:656
SEHK:656Industrials

Assessing Fosun International (SEHK:656) Valuation After 2025 Loss And Shift In Dividend Policy

Fosun International (SEHK:656) has come under closer focus after reporting a larger net loss for 2025, withholding a dividend for the year, and outlining a higher dividend payout framework starting from the 2026 financial year. See our latest analysis for Fosun International. The recent dividend decision and larger 2025 net loss come after a mixed share price pattern, with a 19.5% 1 month share price return and a 9.91% 1 year total shareholder return contrasting with weaker multi year total...
SEHK:6855
SEHK:6855Biotechs

Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum

Recent share performance and business snapshot Ascentage Pharma Group International (SEHK:6855) has drawn investor attention after recent share price moves, with returns of about 13% over the past week and 15% over the past month. The Suzhou based clinical stage biotech focuses on therapies for cancers, chronic hepatitis B and age related diseases in Mainland China. It generated HK$574.12 million in revenue and reported a net loss of HK$1,242.77 million. See our latest analysis for Ascentage...
SEHK:6699
SEHK:6699Medical Equipment

Assessing Angelalign Technology’s Valuation After Strong Earnings And Special Dividend Announcement

Why Angelalign Technology’s latest earnings and dividends matter for investors Angelalign Technology (SEHK:6699) has drawn fresh attention after releasing full year 2025 earnings, alongside a proposed special dividend of HK$4.99 per share and affirming its regular annual payout. See our latest analysis for Angelalign Technology. Since these results and dividend announcements, the share price has gained momentum, with a 30 day share price return of 11.71%, a year to date share price return of...
SEHK:639
SEHK:639Metals and Mining

Undervalued Asian Small Caps With Insider Action For April 2026

As global markets navigate the complexities of Middle East tensions and energy market volatility, Asian small-cap stocks present intriguing opportunities amid a backdrop of mixed economic signals. With key indices showing resilience and geopolitical uncertainties influencing investor sentiment, identifying promising small-cap companies requires a focus on those with robust fundamentals and strategic insider actions that align with current market dynamics.